Under the Paperwork Reduction Act of 1995, no persons are required to re

| INFORMATION DISCLOSURE |
|---|
| STATEMENT BY APPLICANT |
| (Not for submission under 37 CFR 1.99) |
| |

| Application Number | | |
|---------------------------|--|-----------------|
| Filing Date | | 2006-09-21 |
| First Named Inventor Yosh | | ihiro Matsumura |
| Art Unit | | |
| Examiner Name | | |
| Attorney Docket Number | | 101621-25 |

| | | | | Attorney Docket Number | | | 101621-25 | 101621-25 | | |
|----------------------|--|-------------------------------|---------------------------|---|--|---------------------------------|--|--|--|---|
| | | | | | | | | | | |
| | | | | | U.S. | PATENTS | | | Remove | _ |
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue E | Issue Date Name of Patentee or Applicant of cited Document | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | | |
| | 1 | | | | | | | | | |
| If you wisl | h to a | l dd additional U.S. Pater | nt citatio | n inform | ation pl | lease click the | Add button. | | Add | _ |
| | | | U.S.P | ATENT | APPLI | CATION PUBL | LICATIONS | | Remove | _ |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publica Date | tion | n Name of Patentee of Applicant | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | |
| | 1 | | | | | | | Entire | document | |
| If you wisl | h to a | dd additional U.S. Publi | shed Ap | plication | citatio | n information p | lease click the Ad | d buttor | . Add | |
| | | | | FOREIG | SN PAT | TENT DOCUM | ENTS | | Remove | |
| Examiner Initial* | er Cite Foreign Document Country Number ³ Code ² i Kind Date Name of Patente Applicant of citer Document | | e or | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | 74 | | | | | |
| | 1 | 2002 226421 | JP | | A | 2002-08-14 | Daicel Chemical | | Entire document. Cited in International Search Report. Document not provided. | |
| | 2 | 2001 213841 | JP | | A | 2001-08-07 | Asahi Kasei Corp. | | Entire document. Cited in International Search Report. Document not provided. | |
| If you wis | h to a | dd additional Foreign P | atent Do | cument | citation | information pl | ease click the Add | button | Add | |
| | | | NON | I-PATE | NT LITE | RATURE DO | CUMENTS | | Remove | |

| | Application Number | | | |
|---|----------------------|------|----------------|--|
| NEODWATION DIGGS COURT | Filing Date | | 2006-09-21 | |
| NFORMATION DISCLOSURE STATEMENT BY APPLICANT | First Named Inventor | Yosh | hiro Matsumura | |
| Not for submission under 37 CFR 1.99) | Art Unit | | | |
| Not for Submission and of or it is say | Examiner Name | | | |
| | Attorney Docket Numb | er | 101621-25 | |

| Examiner Initials* | Cite No | (bool | de name of the author (in CAPITAL LETTERS), title of the k, magazine, journal, serial, symposium, catalog, etc), date, sher, city and/or country where published. | | T5 |
|-----------------------|---|--------|---|---------------------------------|----|
| | 1 | Orga | nic Synthesis; Pages 18-20. | | |
| | Thurnal Organischeskol Khimik; pages 488-494 and a partial English franslation. | | | | |
| If you wish | to a | id add | fitional non-patent literature document citation information p | elease click the Add button Add | |
| | | | EXAMINER SIGNATURE | | |
| Examiner | Signa | ture | | Date Considered | |
| | | | reference considered, whether or not citation is in conformation and not considered. Include copy of this form with | | |

18e Kind Code of USPTO Patent Documents at year, USPTO_CODY or MEPS 901.04. 2 Enter of this that issued the document, by the involved row (MPD Standard ST3.) 3 "For duplenese petral for counters, the included not be year of the register or many precede the sent amount of the petral document. If the other petral document by the appropriate symbols as indicated on the document under WIPO Standard ST1.6 if possible. 3 Applicant is to place a check mark here if Enginite Imaguage Petral Intelligent ST2.

Application Number Fing Date 2006-09-21 First Number (Not for submission under 37 CFR 1-99) Application Number 2006-09-21 First Number (Not for submission under 37 CFR 1-99) At Unit Examiner Name Attorney Docket Number (191621-25

CERTIFICATION STATEMENT

| Please see 3 | 7 CFR | 1.97 and | 1.98 to make | the appropriate selection(s): | |
|--------------|-------|----------|--------------|-------------------------------|--|
|--------------|-------|----------|--------------|-------------------------------|--|

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

| _ | | | |
|------------|-----------------|---------------------|------------|
| Signature | /bruce s londa/ | Date (YYYY-MM-DD) | 2006-09-21 |
| Name/Print | Bruce S. Londa | Registration Number | 33531 |

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol file and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenar's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.